Shilpa Medicare Q4 PAT may dip 72.3% YoY to Rs. 9.6 cr: Sharekhan
Net Sales are expected to decrease by 15 percent Y-o-Y (down 2.2 percent Q-o-Q) to Rs. 187 crore, according to Sharekhan.12-04-2021
12-04-2021
Shilpa Medicare Ltd - 530549 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- V V KRISHNA CHAITANYADesignation :- Company Secretary and Compliance Officer10-04-2021
Shilpa Medicare Ltd - 530549 - Sub: Compliance Certificate For Half Year Ended 31St March, 2021 Ref: Regulation 7(3) Of SEBI (LODR) Regulations, 2015.
This is to certify that the Company, M/s Shilpa Medicare Limited having its registered office at 12-6-214/A-1, Hyderabad Road, Raichur ,Karnataka - 584135 has been maintaining all the activities in relation to both physical and electronic share transfer facility as specified under Regulation 7(2) of SEBI (LODR) Regulations, 2015 with M/s Kfin Technologies Private Limited, a SEBI Registered Share Transfer Agent, having their corporate office at Selenium Tower B, Plot No.31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 03210-04-2021
SHILPA MEDICARE LTD. - 530549 - Shareholding for the Period Ended March 31, 2021
Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here09-04-2021
India's Shilpa Medicare can make 100-200 million doses of Covid-19 shot
The company's shares jumped as much as 9.2% on India's National Stock Exchange following the news07-04-2021
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates
This is to intimate that the Board of Directors of the Company at its meeting held on 31st March, 2021, approved: 1. The sale of Loba Feinchemie GMBH (a company in Austria), a Step Down Wholly Owned Subsidiary of the Company and to enter into share purchase agreement thereto.31-03-2021
Shilpa Medicare Ltd - 530549 - Closure of Trading Window
With reference to the above subject it is hereby informed that the trading window of Shilpa Medicare Limited will remain closed for dealing in the securities of the Company for all Designated Employees/ Persons and their immediate relatives with effect from 01st April, 2021 till the end of 48 hours from the declaration of the financial results for the Financial Year and Quarter ended 31st March, 202131-03-2021
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Receives US FDA Tentative Approval For Apremilast Tablets, 10 Mg, 20 Mg, And 30 Mg
This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Apremilast Tablets, 10 mg, 20 mg, and 30 mg dated 04 Mar 2021. The ANDA was filed as 'First to File' submission on NCE -1 date to seek eligibility for 180 days exclusivity. Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene used in the treatment of 'psoriatic arthritis' as recommended in the label approved by FDA. According to IQVIA MAT Q2 2020 data, the US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is approximately US $2.4 billion.05-03-2021
Shilpa Medicare enters women's intimate cleansing segment with SwatchShil
The soap-free, alcohol-free solution with a pH of 3.70.5 is ideal for women's intimate care; to be available in 100 ml spray packs in jasmine, floral fragrance04-03-2021
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited Enters Into Gynecology Segment By Launching Its First Women Intimate Cleansing Spray In India Under The Brand Name 'Swatchshil'
Shilpa Medicare Limited, a research-led global integrated pharmaceutical company, today announced launch of India's First Women intimate cleansing spray under the brand name 'SwatchShil' and shall be available in Jasmine and Floral Fragrance in 100ml Spray pack.'SwatchShil' intimate Cleansing Spray is a Soap-free and alcohol-free solution with a pH of 3.7+-0.5, which is ideal for the Women intimate area, helps in maintaining the optimum pH level and avoids vaginal discomfort and effectively maintain intimate hygine. Shilpa's 'SwatchShil' presented first time in India in an innovative 'Bag on Valve' spray 'SwatchShil' has differentiated advantage of hands-free application for enhanced utility and ease of use unlike current products available in the market. While the market size of intimate hygiene is near about Rs. 80 crores, 'SwatchShil' is made available at Major Chemist's outlet in India. It is also available online for Purchase at www.shilpacare.in, Amazon, Flipkart...04-03-2021